Ashvattha branches out with $69M series B for dendrimer therapies

Dendrimer therapeutics company Ashvattha will put its new $69 million series B round toward continued clinical development of a pair of lead programs, with a separate deal in China adding non-dilutive capital to extend its runway.

The funding allows Ashvattha Therapeutics Inc. to advance a pipeline of hydroxyl dendrimer therapeutics (HDTs), a class of medicines the company views as precision therapies that can be targeted to inflammatory cells in specific tissues. Two have reached the clinic...